Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding pyoderma gangrenosum is primarily due to its rarity, which affects fewer than 5,000 people in the U.S. As a result, systematic clinical studies have been scarce, making it difficult to establish a comprehensive understanding of its clinical features and genetic basis. Additionally, the inflammatory nature of the condition can overlap with other dermatological disorders, complicating diagnosis and characterization.
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently three orphan drugs designated for pyoderma gangrenosum: infliximab, spesolimab-sbzo, and Vilobelimab, which are in various stages of development. In addition, there are five active clinical trials investigating potential treatments and management strategies for PG. For more information, you can explore ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=pyoderma%20gangrenosum.
Actionable guidance for navigating care for pyoderma gangrenosum
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding pyoderma gangrenosum is primarily due to its rarity, which affects fewer than 5,000 people in the U.S. As a result, systematic clinical studies have been scarce, making it difficult to establish a comprehensive understanding of its clinical features and genetic basis. Additionally, the inflammatory nature of the condition can overlap with other dermatological disorders, complicating diagnosis and characterization.
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently three orphan drugs designated for pyoderma gangrenosum: infliximab, spesolimab-sbzo, and Vilobelimab, which are in various stages of development. In addition, there are five active clinical trials investigating potential treatments and management strategies for PG. For more information, you can explore ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=pyoderma%20gangrenosum.
Actionable guidance for navigating care for pyoderma gangrenosum
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding pyoderma gangrenosum is primarily due to its rarity, which affects fewer than 5,000 people in the U.S. As a result, systematic clinical studies have been scarce, making it difficult to establish a comprehensive understanding of its clinical features and genetic basis. Additionally, the inflammatory nature of the condition can overlap with other dermatological disorders, complicating diagnosis and characterization.
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently three orphan drugs designated for pyoderma gangrenosum: infliximab, spesolimab-sbzo, and Vilobelimab, which are in various stages of development. In addition, there are five active clinical trials investigating potential treatments and management strategies for PG. For more information, you can explore ongoing studies at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=pyoderma%20gangrenosum.
Actionable guidance for navigating care for pyoderma gangrenosum
To manage pyoderma gangrenosum effectively, it is important to seek a dermatologist with expertise in inflammatory skin diseases, particularly those familiar with PG. Engaging with a healthcare provider who understands the nuances of this condition can be beneficial. Additionally, you may want to explore clinical trial opportunities to access cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide valuable information and support. While no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning pyoderma gangrenosum
Updated Feb 6, 2026
A rare case report details fasciitis-like primary breast pyoderma gangrenosum, contributing to the understanding of this uncommon condition. This study may provide insights for clinicians dealing with similar rare dermatological cases.